Publication | Open Access

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study

UrologyPancreatic CancerPhase IiGastrointestinal OncologyMedicineClinical TrialsPharmacotherapyAdvanced Pancreatic CancerCancer TreatmentMulticenter StudyOncologyRadiation OncologyHealth Sciences